Arvinas (ARVN) Share-based Compensation (2017 - 2026)
Arvinas' (ARVN) quarterly Share-based Compensation came in at $12.1 million in Q1 2026, down 19.33% year-on-year from $15.0 million in Q1 2025, and up 42.35% quarter-over-quarter from $8.5 million in Q4 2025.
Arvinas (ARVN) Share-based Compensation (2017 - 2026) Analysis & Trends
Arvinas' Share-based Compensation history runs 10 years deep, the most recent figure standing at $12.1 million for Q1 2026.
- On a quarterly basis, Share-based Compensation fell 19.33% year-over-year to $12.1 million in Q1 2026; TTM through Mar 2026 was $41.1 million, a 51.42% decrease from a year earlier, with the FY2025 full-year figure at $44.0 million, down 50.11% from the prior year.
- Share-based Compensation grew to $12.1 million in Q1 2026 per ARVN's latest filing, from $8.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $24.7 million in Q3 2024 and bottomed at $8.5 million in Q4 2025.
- The 5-year median for Share-based Compensation is $18.3 million (2023), against an average of $17.1 million.
- Across the five-year window, Share-based Compensation surged 61.17% in 2022 and sank 63.52% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $20.1 million in 2022, then fell by 16.92% to $16.7 million in 2023, then soared by 39.52% to $23.3 million in 2024, then tumbled by 63.52% to $8.5 million in 2025, then soared by 42.35% to $12.1 million in 2026.
- Per Business Quant, the three latest ARVN Share-based Compensation figures stand at $12.1 million (Q1 2026), $8.5 million (Q4 2025), and $10.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | 12.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.10 Mn |
| Mar 31, 2026 | 12.10 Mn |
| Dec 31, 2025 | 8.50 Mn |
| Dec 31, 2025 | 8.50 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Sep 30, 2024 | 24.70 Mn |
| Sep 30, 2024 | 24.70 Mn |
| Jun 30, 2024 | 21.60 Mn |
| Jun 30, 2024 | 21.60 Mn |
| Mar 31, 2024 | 18.60 Mn |
| Mar 31, 2024 | 18.60 Mn |
| Dec 31, 2023 | 16.70 Mn |
| Dec 31, 2023 | 16.70 Mn |